SBI Healthcare Opportunities Fund
The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space.
Growthvine rating: 4/5 — ranked #10 of 87 in category.
Fund basics
| Category | Equity: Sectoral |
|---|
| NAV | ₹472.93 (as of 2026-10-23) |
|---|
| AUM | ₹5,870 Cr |
|---|
| Expense ratio | 1.57% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Tanmaya Desai |
|---|
| Exit load | 0.5% for redemption within 15 days |
|---|
Performance & risk
| 5-year annualised return | 16.55% |
|---|
| Sharpe ratio | 1.03 |
|---|
| Standard deviation | 14.76% |
|---|
| Max drawdown | −63.37% |
|---|
| Alpha | 2.04 |
|---|
| Beta | 0.87 |
|---|
Over 5 years, captured 97.2% of NIFTY Pharma's upside and 77.0% of its downside.
Market cap allocation
| Large cap | 33.8% |
|---|
| Mid cap | 26.9% |
|---|
| Small cap | 39.3% |
|---|
Concentration
| Top 5 holdings | 33.0% |
|---|
| Top 10 holdings | 51.8% |
|---|
| Total holdings | 35 |
|---|
Top holdings
- Sun Pharmaceutical Industries Ltd. — 11.1%
- Divis Laboratories Ltd. — 7.9%
- TREPS — 6.4%
- ACUTAAS CHEMICALS LIMITED — 5.0%
- Apollo Hospitals Enterprises Ltd. — 4.4%
- Torrent Pharmaceuticals Ltd. — 4.4%
- Cipla Ltd. — 4.4%
- Laurus Labs Limited — 4.1%
- Max Healthcare Institute Limited — 3.8%
- Aurobindo Pharma Ltd. — 3.4%
Top sectors
- Pharma & Biotech — 63.1%
- Healthcare — 27.5%
- Chemicals — 5.0%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 12.2% | Q1 (Top) | #5 of 76 |
| 2025 | −3.5% | Q3 | #48 of 69 |
| 2024 | 42.2% | Q1 (Top) | #5 of 58 |
| 2023 | 38.2% | Q2 | #20 of 48 |
| 2022 | −6.0% | Q3 | #33 of 46 |